SCHEMBL6073880

SCHEMBL6073880

CC(C)(C)OC(=O)N1CCN(c2ccc(Nc3ncc4ccc(NC(=O)NC5CCCCC5)nc4n3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 3/20 0.54
CCND1 P24385 3/20 0.54
CCND3 P30281 2/20 0.54
CCND2 P30279 1/20 0.54
CDK2 P24941 4/20 0.50
CCNK O75909 1/20 0.50
CCNA2 P20248 1/20 0.50
CDK9 P50750 1/20 0.50
CDK6 Q00534 1/20 0.50
SYK P43405 8/20 0.49
CCNE1 P24864 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
JAK2 O60674 1/20 0.45
JAK3 P52333 1/20 0.45
EGFR P00533 1/20 0.45
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073855 0.99 CDK4 (0.54) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6074659 0.89 SYK (0.58) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6074087 0.88 CCND3 (0.62) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6074137 0.88 AURKB (0.41) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6074141 0.88 AURKB (0.41) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6074236 0.87 CDK2 (0.53) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6073805 0.87 CCND3 (0.63) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6073911 0.87 CDK2 (0.54) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6073956 0.87 CCND3 (0.53) CDK4CCND1CCND3CCND2CDK2
SCHEMBL6073878 0.87 CCND3 (0.53) CDK4CCND1CCND3CCND2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CCND3 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.